Icon of the Instituts for Quality and Efficiency in Health Care

Report

Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

Status
Status: Commission completed
Project no.
A09-05
Last updated

Report documents

  1. Executive summary of the final report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 101 kB, EN, PDF
    Download file : Executive summary of the final report (PDF-Dokument, 101 kB, EN, PDF)

  2. Final report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 1 MB, DE, PDF
    Download file : Final report (PDF-Dokument, 1 MB, DE, PDF)

  3. Documentation and evaluation on the preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 5 MB, PDF
    Download file : Documentation and evaluation on the preliminary report (PDF-Dokument, 5 MB, PDF)

  4. Executive summary of the preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 139 kB, DE, PDF
    Download file : Executive summary of the preliminary report (PDF-Dokument, 139 kB, DE, PDF)

  5. Preliminary report

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 1 MB, DE, PDF
    Download file : Preliminary report (PDF-Dokument, 1 MB, DE, PDF)

  6. Report plan version 1.0

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 136 kB, PDF
    Download file : Report plan version 1.0 (PDF-Dokument, 136 kB, PDF)

  7. Documentation and appraisal of comments on the preliminary report plan

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 2 MB, PDF
    Download file : Documentation and appraisal of comments on the preliminary report plan (PDF-Dokument, 2 MB, PDF)

  8. Preliminary report plan

    Cholinesterase inhibitors in Alzheimer's disease - supplementary commission: rivastigmine patches and galantamine

    published on
    Document type
    PDF-Dokument, 141 kB, DE, PDF
    Download file : Preliminary report plan (PDF-Dokument, 141 kB, DE, PDF)

Press releases

Galantamine and rivastigmine patches: positive influence on cognition possible

But for both the drugs used to treat Alzheimer’s disease, there is also proof of harm
Press release

Additional information

IQWiG health information

How effective are cholinesterase inhibitors?

Project details

Project no.
A09-05
Commission
Commission awarded on 18.12.2009 by the Federal Joint Committee (GBA).
Report type
Report
Status
Commission completed
Department/Division
Drug Assessment
Topic
Head and nerves

Connected Projects

  1. Report

    Cholinesterase inhibitors in Alzheimer's disease

    Project no.
    A05-19A
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page